Results 41 to 50 of about 7,793 (208)

Cell Cycle- and Cancer-Associated Gene Networks Activated by Dsg2: Evidence of Cystatin A Deregulation and a Potential Role in Cell-Cell Adhesion [PDF]

open access: yes, 2015
This work was supported by grants from the National Institutes of Health (Mahoney, R01AR056067; Riobo, RO1 GM088256). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the ...
A Pavlova   +74 more
core   +3 more sources

Neurodermatitis Sirkumskripta Pada Wanita Dengan Hipertensi Grade I Terkontrol [PDF]

open access: yes, 2014
Latar Belakang. Neurodermatitis sirkumskripta atau juga dikenal dengan liken simpleks kronis adalah penyakit peradangan kronis pada kulit, gatal, sirkumskripta, dan khas ditandai dengan likenifikasi.
Damayanti, I. T. (Idhar)
core  

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

open access: yesCA: A Cancer Journal for Clinicians, Volume 75, Issue 5, Page 436-460, September/October 2025.
Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease.
Pawel Kordowitzki   +6 more
wiley   +1 more source

Dapsone induced cholangitis as a part of dapsone syndrome: a case report

open access: yesBMC Gastroenterology, 2003
Background Dapsone can rarely cause a hypersensitivity reaction called dapsone syndrome, consisting of fever, hepatitis, exfoliative dermatitis, lymphadenopathy and hemolytic anemia.
Choudhuri Gourdas   +3 more
doaj   +1 more source

Cyclosporine A-induced Hair Repigmentation in a Patient with Dermatitis: A Case Report

open access: yesOman Medical Journal, 2023
Cyclosporine A is an immunosuppressant drug known to cause several side effects. One of the most common side effects is hypertrichosis, with a rare presentation of hair repigmentation rarely presenting.
Raqiya Al Rajaibi, Balaqis Al Saadi
doaj   +1 more source

Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency [PDF]

open access: yes, 2008
One of the severe combined immunodeficiencies (SCIDs), which is caused by a genetic defect in the signal transduction pathways involved in T-cell activation, is the ZAP70 deficiency.
A Fischer   +29 more
core   +5 more sources

Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

open access: yesChronic Diseases and Translational Medicine, Volume 11, Issue 3, Page 173-185, September 2025.
The interaction of tislelizumab with PD‐1/PD‐L1 in the tumor microenvironment. Tislelizumab targets PD‐1 on T cells, blocking its interaction with PD‐L1 on tumor cells. This action is facilitated by a modified F(ab) region that limits Fc‐γ receptor binding, thereby enhancing the antitumor immune response. ABSTRACT Tislelizumab is a next‐generation PD‐1
Thy T. Nguyen   +4 more
wiley   +1 more source

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population. [PDF]

open access: yes, 2019
BackgroundAcne vulgaris (acne) is a common skin condition in children and adolescents. Efficacy of tretinoin is well documented in studies that included pediatric patients (12-18 years of age). With acne routinely presenting in younger patients, data are
Bhatt, Varsha   +4 more
core   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

open access: yesCancer Science, Volume 116, Issue 8, Page 2189-2197, August 2025.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy